Welcome to our dedicated page for Marinus Pharmaceuticals news (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmaceuticals stock.
Marinus Pharmaceuticals, Inc. (MRNS) is a clinical-stage biopharmaceutical company committed to improving the lives of patients suffering from epilepsy and neuropsychiatric disorders. The company is at the forefront of developing and commercializing ganaxolone, a novel therapeutic aimed at addressing a range of conditions including epileptic seizures in both adults and children, as well as postpartum depression in women.
One of the significant milestones for Marinus came on June 29, 2017, when the U.S. Food and Drug Administration (FDA) granted orphan drug designation to ganaxolone for the treatment of CDKL5 disorder. This severe and rare genetic disorder affects children from an early age, leading to difficult-to-control seizures and neuro-developmental impairments. Orphan drug designation is a status granted by the FDA's Office of Orphan Products Development to novel drugs that treat rare diseases or conditions impacting fewer than 200,000 patients in the U.S. This designation not only underscores the urgent need for treatment options for CDKL5 disorder but also provides Marinus with various development incentives including tax credits and market exclusivity.
Marinus Pharmaceuticals manages its operations in a single segment focused on the identification and development of neuropsychiatric therapeutics. Beyond CDKL5 disorder, the company is advancing ganaxolone for multiple epilepsy and neuropsychiatric indications. These include adjunctive therapy for drug-resistant focal onset seizures, status epilepticus, Fragile X Syndrome, and PCDH19-related epilepsy.
With an unwavering focus on patient well-being, Marinus is poised to deliver groundbreaking solutions that address some of the most challenging neurological and psychiatric conditions. The company continues to make strides in clinical research and aims to bring much-needed therapies to market, demonstrating its commitment to transforming patient care.
Marinus Pharmaceuticals (Nasdaq: MRNS) announced its participation in several upcoming healthcare conferences. The Truist Virtual Fireside Chat is scheduled for October 23, 2020, featuring key management members. Following this, the company will hold one-on-one meetings at Guggenheim's 2nd Annual Neuro/Immunology Day on November 16, 2020. Finally, they will present at the Jefferies London Healthcare Conference on November 18, 2020. Marinus is focused on developing innovative therapies for rare seizure disorders, notably through its lead product, Ganaxolone.
Marinus Pharmaceuticals (MRNS) announced the grant of non-qualified stock options to 11 new employees, totaling 144,050 shares as inducements for employment. The options include 138,250 shares priced at $14.53, reflecting the stock's closing price on October 9, 2020, and 5,800 shares priced at $14.86, based on the closing price on October 12, 2020. The options will vest 25% on the one-year anniversary of employment and the remaining 75% monthly over the next three years. The grants comply with Nasdaq rules and are intended to attract talent to aid in the company's mission to develop treatments for rare seizure disorders.
Marinus Pharmaceuticals (MRNS) provided a pipeline update announcing key advancements in its clinical trials. The Phase 3 pivotal trial for status epilepticus is set to begin in Q3 2020, with 124 patients planned for enrollment. Additionally, the company is on-track to report topline data for the CDKL5 Deficiency Disorder trial, which has already enrolled 101 patients. A Phase 2 trial for Tuberous Sclerosis Complex started with the first patient enrolled, while patient enrollment for the PCDH19 trial has increased to 25-30 patients.
Marinus Pharmaceuticals (Nasdaq: MRNS) will host a webinar on June 30, 2020, from 8 AM to 10:30 AM ET, focusing on its pipeline programs for treating rare seizure disorders. Key topics include Status Epilepticus, CDKL5 Deficiency Disorder, and Tuberous Sclerosis Complex. Notable speakers include Dr. Scott Braunstein and Dr. Joe Hulihan. The event aims to provide a clinical and commercial overview, highlighting Marinus' innovative therapeutic approach utilizing Ganaxolone, a drug in development for acute and chronic care settings.
Marinus Pharmaceuticals (Nasdaq: MRNS) announced their participation in SVB Leerink’s 2nd Annual CNS Forum on June 23, 2020, at 3:20 PM ET. The presentation, titled "A Pipeline Update," will feature CEO Scott Braunstein and CMO Joe Hulihan discussing the company's innovative therapeutics for rare seizure disorders, particularly focusing on Ganaxolone. This drug acts on GABAA receptors and is being developed in various forms to enhance treatment for both adult and pediatric patients. Marinus is initiating multiple clinical trials, including a Phase 3 trial for children with CDKL5 deficiency.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced the grant of a stock option to Martha Manning, the new Vice President, General Counsel, and Secretary, to purchase 300,000 shares at an exercise price of $2.52 per share. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), aims to incentivize Manning as a material condition of her employment. The stock option vests over four years, with 25% after one year and the remaining 75% in monthly installments. Marinus focuses on developing ganaxolone, a treatment for rare seizure disorders, currently conducting multiple clinical trials.
Marinus Pharmaceuticals (MRNS) announced the appointment of Martha Manning as Vice President, General Counsel, and Secretary. Manning brings over 20 years of legal experience in the biopharma sector, previously serving at Achillion Pharmaceuticals and ICeutica. CEO Scott Braunstein expressed optimism that her leadership will be crucial as they navigate upcoming milestones for ganaxolone, aimed at treating orphan seizure disorders. Marinus is advancing multiple clinical trials for ganaxolone, highlighting its commitment to innovative therapeutic development.
Marinus Pharmaceuticals (NASDAQ: MRNS) announced the closing of an underwritten public offering of 18.4 million shares at $2.50 per share, raising approximately $46 million in gross proceeds. The offering included an option for underwriters to purchase an additional 2.4 million shares. Proceeds will be used for product development, working capital, and general corporate purposes. Cowen and Cantor Fitzgerald acted as lead managers for the offering, conducted under SEC registration.
Marinus Pharmaceuticals (Nasdaq: MRNS) has announced plans for an underwritten public offering of its common stock to fund the development of its product candidates and general corporate purposes. The offering is contingent on market conditions, with underwriters granted a 30-day option to purchase an additional 15% of shares. Lead managers include Cowen and Cantor Fitzgerald. Proceeds will support clinical trials, acquisitions, and working capital. This offering follows a previously effective shelf registration statement with the SEC.
FAQ
What is the current stock price of Marinus Pharmaceuticals (MRNS)?
What is the market cap of Marinus Pharmaceuticals (MRNS)?
What is Marinus Pharmaceuticals, Inc.?
What is ganaxolone?
What is CDKL5 disorder?
What does orphan drug designation mean?
Which other conditions is ganaxolone being developed for?
When did Marinus receive orphan drug designation for ganaxolone?
What incentives does orphan drug designation provide?
What is the primary area of focus for Marinus Pharmaceuticals?
Why is ganaxolone significant?
How does Marinus Pharmaceuticals impact patient care?
